- Additional contract for a new clinical trial
- Parsortix system to be used for longitudinal monitoring of patients with unresectable solid tumours
ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that the Company has secured an additional contract with its first large-scale pharma services customer. The customer, a pharma company with numerous cancer drugs under development and revenues exceeding US$1B per annum, has again selected ANGLE's Parsortix system to undertake longitudinal monitoring (i.e. before, during and after drug intervention) of patients with certain unresectable solid tumours in a new Phase Ib dose-escalation study using its investigational drug in combination with immuno-oncology agents. Once the recommended dose has been determined, the study will progress to an expansion stage.
The additional contract is expected to be worth up to US$1.2M over a multi-year period. The new work relates to the successful progression of one of the smaller Phase I studies in the original contract announced in April 2021. This dose-escalation study, with expansion stage, is scheduled to begin in the next few weeks and the customer expects to provide samples from each patient for analysis by ANGLE at as many as seven separate timepoints. As with the previous contracts, ANGLE anticipates that this further Phase Ib study, if successful, could progress to larger Phase II studies and, potentially, much larger Phase III studies.
As with the original contract, the agreed services cover the capture, harvest and analysis of circulating tumour cells (CTCs) and CTC clusters. Samples will be shipped from multiple study centres to ANGLE's clinical laboratories in the UK and United States for analysis using the Parsortix system.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"We have previously indicated that we expect repeat business from our pharma services customers. We believe that the Parsortix liquid biopsy has particular advantages in capturing intact cancer cells, including mesenchymal cells and clusters, and provides the opportunity for longitudinal testing in a clinical setting. This is not possible with tissue biopsy.
The additional contract from our first large-scale pharma customer, as well as ongoing discussions with multiple potential new customers, validates ANGLE's belief that longitudinal monitoring of CTCs is a highly attractive proposition for the pharma industry looking for new insights in cancer drug trials.
We are very pleased with the increasing levels of interest from pharma companies in our CTC analysis services following FDA clearance of the Parsortix system and look forward to announcing further progress on the expansion of this important business area for ANGLE in due course."